• Protocol AZ 5077IL/0089 (Clears Trial) A Multicenter, open label, flexible dose, parallel group evaluation of the cataractogenic potential of Quetiapine fumarate (SEROQUEL TM ) and Risperidone (RISPERDAL TM ) in the long term treatment of patients with Schizophrenia and Schizoaffective Disorder.
  • Protocol CN138012-016: A Randomized, Double Blind Comparison of the efficacy and Safety of Aripiprazole Intramuscular Formula, Haloperidol, or Placebo in the treatment of Acutely Agitated Patients with a Diagnosis of Schizophrenia or Schizoaffective Disorder.
  • Protocol AZ 5077IL/0089 (Clears Trial) A Multicenter, open label, flexible dose, parallel group evaluation of the cataractogenic potential of Quetiapine fumarate (SEROQUEL TM ) and Risperidone (RISPERDAL TM ) in the long term treatment of patients with Schizophrenia and Schizoaffective Disorder.